Neurocrine(NBIX) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Neurocrine Biosciences Reports First Quarter 2024 Financial Results INGREZZA® (valbenazine) First Quarter Net Product Sales of $506 Million Representing 23% Year-Over- Year Growth INGREZZA® SPRINKLE (valbenazine) Capsules Approved by the U.S. FDA Crinecerfont New Drug Applications for the Treatment of Congenital Adrenal Hyperplasia Submitted to the U.S. FDA Positive Phase 2 Top-Line Data for NBI-1065845, a Potential First-In-Class AMPA Positive Allosteric Modulator, in Adults with Major Depress ...